

Program of the 13rd conference of the International Society for the Study of Drug Policy, Paris, France

Day 1: Wednesday, May 22nd					
8:00 to 9:00 AM	Registration				
9:00 to 9:20 AM	Opening and welcome Marie Jauffret-Roustide, Paris Conference Host Alex Stevens, President of the ISSDP Anne Souyris, Paris Deputy Major in charge of health issues				
9:20 to 10:20 AM	First plenary session: “The ontological politics of drug policy: a critical realist approach” Keynote presentation by Alex Stevens, Professor in Criminal Justice, University of Kent in conversation with Kari Lancaster, Senior Research Fellow at UNSW and Rosalie Liccardo Pacula, Co-Director of the RAND Drug Policy Research Center Chair: Alison Ritter				
10:20 to 10:50 AM	Break				
10:50 to 12:20 PM	Exploring changes in the US 'heroin' risk environment: HIV, drug supply, polysubstance use and overdose	The roles of measures and perceptions in Cannabis regulation	Cryptomarkets: supply, demand, and hidden spaces of transaction	New models for public health treatment funding and enforcement	Age, gender, family and perception factors in access to drug treatment and services
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	Dan Ciccarone	Beau Kilmer	Gary Potter	Andrew McAuley	Karine Bertrand
	<u>Dan Ciccarone</u> Missed opportunities: viral transmission risks among a new cohort of injectors in the United States “heroin” epidemic	<u>Yuyan Shi & D. Liang</u> The associations between recreational cannabis commercialization and cannabis exposures reported to the US National Poison	<u>Michala Kowalski,</u> J. Aldridge, R. Coomber, J. Martin & M.J. Barratt Cryptomarkets, ignorance and harm: does drug expertise matter more in a	<u>Osasuyi Dirisu & A. Klein</u> Non-medical use of tramadol in West Africa: The tensions between law enforcement, illegal supply pathways and	Mélanie Quétier, M. Bouchon, N.N. Lwin & S.N. Pan Sociocultural and religious norms and values at the foundation of repression and

		Data System, 2010-2017	high drug availability setting?	public health.	violence towards people who use drugs in Kachin State, Myanmar
	<p><u>Dan Rosenblum</u></p> <p>The rapidly changing US illicit opioid market and the potential for an improved early warning system: evidence from Ohio drug crime labs</p>	<p><u>David-Martin Milot & M. Jauffret-Roustide</u></p> <p>Psychoactive substances and their regulatory systems: how social representations influence policies in France</p>	<p><u>Shann Hulme, C.E. Hughes & S. Nielsen</u></p> <p>The price of drugs supplied on the pharmaceutical black market: an Australian case study</p>	<p><u>Chris Wilkins & M. Rychert</u></p> <p>The risks of cannabis industry funding of community and drug treatment services – Insights from gambling</p>	<p><u>Meredith Meacham, K. Lynch, P. Coffin & E. Riley</u></p> <p>An examination of fentanyl metabolites in a primarily crack cocaine-using population of unstably housed women in San Francisco, USA</p>
	<p><u>Georgiy Bobashev</u></p> <p>Polydrug use patterns among prescription opioid misusers and heroin users. Results from the National Household Survey of Drug Use and Health</p>	<p><u>Lindsey Beltz, C. Mosher & J. Schwartz</u></p> <p>Assessing perceived effects of 1-502: A survey on recreational cannabis in Washington State</p>	<p><u>Patrick Shortis</u></p> <p>Towards an understanding of resilience in cryptomarkets</p>	<p><u>Jorge Mantilla</u></p> <p>Supply resilience and therapeutic policing: the new face of war on drugs in Colombia</p>	<p><u>Maria Caiata-Zufferey, M. Luciani, P. di Giulio, L. Pezzoli, C. Prandi & A. Moriggia</u></p> <p>The aging process of people who use drugs in opioid substitution treatment: design and preliminary results of an interdisciplinary and participatory research project in Southern Switzerland</p>
	<p><u>Jay Unick</u></p> <p>Divergence in deaths vs. hospitalizations for heroin and other opiate overdoses. Changes in risk or problems of classification?</p>	<p><u>Clayton Mosher</u></p> <p>Youth use of marijuana in Washington State - Trends and correlates</p>	<p><u>Nicolae Craciunescu</u></p> <p>Drugs in the context of consumer culture: the sign-value of the products sold on the Darknet marketplaces</p>	<p><u>Aysel Sultan</u></p> <p>The stake of a non-standard comparative approach: Treatment policies of Azerbaijan and Germany</p>	<p><u>Sarah A. Daniels, T.A. Sanchez, M. St. Pierre & Z. Walsh</u></p> <p>Maternal cannabis use: Examining the relationships between cannabis use, attachment, and parenting outcomes in Canadian mothers</p>

12:20 PM to 1:30 PM	Lunch break				
12:20 PM to 1:30 PM	Poster presentations				
1:30 PM to 3 PM	National and cultural contexts: comparative drug policy analysis	Policy controversies about harm reduction	Cannabis: consumer experiences and evolving perceptions	Legalizing, implementing, and assessing substitution treatment	Measuring, treating, and prohibiting drug use among marginalized and migrating drug users
Room	Auditorium	R2-01	R1-13	R-14	R1-15
Chair	Scott Burris	Naomi Burke-Shyne	David-Martin Milot	Polly Radcliffe	Anne Line Bretteville-Jensen
	<u>Siobhan Callaghan</u> Issues in comparing national drug policies: Utilising typologies to identify drug policy regimes and explore cultural contexts	<u>Tuukka Tammi</u> Political process on launching drug consumption rooms in Helsinki	<u>Ashely Granville, J. Chopin, P. Esseiva, R. Udrisard, F. Zobel, & M. Jendly</u> Lights on small-scale cannabis growers: Findings from a European web survey and face to face interviews	<u>Sarah Heins & R. Castillo</u> Evaluation of the impact of morphine equivalent daily dose policies on high dose opioid prescribing	<u>Louise Christensen, B. Bjerge & E. Houborg</u> Agents of care and control within the welfare State: The interrelation between drug policies, social policies and services towards people who experience social marginalization
	<u>Kim Moeller</u> Sisters are never alike? – Drug control intensity in the Nordic countries	<u>Marie Jauffret-Roustide & I. Cailbault</u> Controversy over drug consumption rooms: from assessing social acceptability to sharing urban spaces	<u>Daniel Bear</u> Young people's decision making about cannabis	<u>Atul Ambekar, R. Rao, A. Agrawal, S. Singh & M. Varshney</u> Ambiguities in the legal frameworks for treatment of drug use disorders versus other mental health conditions: Reflections from the recently enacted mental	<u>Charlotte De Kock</u> Monitoring migration-related indicators in European drug treatment: Identifying pitfalls and challenges in registration, data collection and database coupling methods

				healthcare law in India	
	<p><u>Clara Musto</u> Advocacy coalitions moral foundations: developing cross-cultural variations in drug policy change explanations</p>	<p><u>Esben Houborg, M. Bancroft & J. Wielandt Holt</u> The impact of a local drug policy on drug users' everyday life on an open drug scene</p>	<p><u>Sharon R. Sznitman, Y. Ben Baruch, T. Greene & M. Gelkopf</u> The association between physical pain and cannabis use in daily life: An experience sampling method</p>	<p><u>Pedro Mateu-Gelabert, H. Guarino & S. Campos</u> Atención VIH (A!VIH): An integrated Seek, Test, Treat and Retain (STTR) - Medication-Assisted Treatment (MAT) intervention for PWID in Latin America.</p>	<p><u>Sarah Tosh</u> Drug prohibition and the criminalization of immigrants: The compounding of drug war disparities in the modern United States deportation regime</p>
	<p>R. Kert, A. Lehner, <u>Brendan Hughes</u> & O. Dalbinoë Comparing drug trafficking penalties across the EU</p>	<p><u>Tara Marie Watson, L. Barnaby, A. M. Bayoumi, L. Challacombe, A. Wright & C. Strike</u> “This is a health service. Leave it alone”: Staff and client views on policing boundaries involving supervised consumption services</p>	<p><u>Sebastian Aguiar</u> What do people think afterwards? Characterizing public opinion on cannabis regulation in Uruguay through open-ended responses</p>	<p><u>Samara Mayer, A. Fowler, J. Boyd & R. McNeil</u> Understanding motivations for the initiation of injectable opioid agonist treatment: An ethnographic study of patient care experiences in Vancouver, Canada</p>	<p><u>S. MacGregor & Aileen O’Gorman</u> Social policy paradigms: framing perceptions and policies towards people who are poor and use drugs.</p>
3 PM to 3:30 PM	Break				
3:30 PM to 5:00 PM	Illicit drugs and the transformation of war economies	Opioid use and responses - Opioid crisis	Methods in measurements and assessments of largescale drug policy	Polyuse and issues in specific injecting communities	Medical cannabis: use and regulations
Room	Auditorium	R2-01	R1-13	R1-14	R1-15
Chair	John Collins	Peter Reuter	Brandon Hughes	Fay Dennis	Sharon Sznitzman

	<p><u>John Collins</u></p> <p>Theorising fragmentation and change in global drug control</p>	<p><u>Bryce Pardo</u></p> <p>Why fentanyl in North America? Why now?</p>	<p><u>Ayden Scheim</u>, N. Maghsoudi, S. Churchill, Z. Marshall & D. Werb</p> <p>What matters and what has been measured? A systematic review of research on the impacts of implementing drug decriminalization or regulation</p>	<p><u>Jennifer Havens</u> & H. Knudsen</p> <p>Recent transition to methamphetamine use among nonmedical prescription opioid users from Appalachian Kentucky, 2008-2019</p>	<p><u>Bernd Werse</u>, L. Klaus & G. Kamphausen</p> <p>Hybrid users – results from a qualitative study on the blurred boundaries between recreational and medical cannabis use</p>
	<p><u>Jasmine Bhatia</u></p> <p>Unsettling the peace? The role of illicit economies in peace processes</p>	<p><u>Jirka Taylor</u> & P. Reuter</p> <p>International experiences with fentanyl</p>	<p><u>Hannah Knudsen</u> & J. Havens</p> <p>Using conjoint analysis to study health policy changes: an example from a cohort of persons who use drugs</p>	<p><u>Katherine McLean</u>, K. Rigg, S. Monnat, A. Verdery & G. Sterner</p> <p>“Pushed in the same way”: Exploring the role of cocaine in heroin initiation, continuation, and desistance</p>	<p><u>Frédérique Bawin</u></p> <p>Accessing illicit medicines. The search for medicinal cannabis in Flanders</p>
	<p><u>Jonathan Goodhand</u></p> <p>Re-imagining the narco frontier</p>	<p><u>Rosanna Smart</u> & B. Kilmer</p> <p>Can heroin-assisted treatment help reduce fentanyl deaths in the US?</p>	<p><u>Nicola Singleton</u>, D. Ballotta, C. Costa Storti, E. Quigley & L. Vandam</p> <p>“Help! I have to evaluate our drug strategy” – the EMCDDA approach to promoting an evaluation culture in drug policy development in Europe</p>	<p><u>Laurent Gaissad</u>, T. Madesclaire & M. Milhet</p> <p>Combining strategies: echoes from the APACHES chemsex study in France</p>	<p><u>Chelsea Cox</u></p> <p>One stream or two stream? Legal and policy considerations for maintaining a separate medical cannabis access stream in Canada</p>
	<p><u>Eric Gutierrez</u></p> <p>The paradox of illicit economies</p>		<p><u>Davide Fortin</u> & M. Pardal</p> <p>In between recreational and medical cannabis supply models: is the Cannabis Social Club a potential buffer against market distortions?</p>	<p><u>Roberto Abadie</u></p> <p>Poverty, homelessness and barriers to access and retention in opioid agonist therapy for people who inject drugs</p>	<p><u>Mark Monaghan</u>, E. Wincup & I. Hamilton</p> <p>Scandalous decisions: Understanding UK medicinal cannabis policy</p>
5 PM to 6 PM					

	ISSDP General Assembly
7 PM to 9 PM	Reception